Security
Artiva Biotherapeutics, Inc. Common Stock · ARTV
ARTVNASDAQCommon stockCurrentCIK 1817241Updated Oct 28, 2026
ARTV price & chart
Loading TradingView…
NASDAQ:ARTV on TradingView ↗About the company
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK® (AB-101), the Company’s lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. On October 27, 2026, Artiva announced the discontinuation of further clinical development of AlloNK and the initiation of an evaluation of strategic alternatives. Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
In the news
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities
Items 2.02, 2.05, 9.01
4 filing
4 filing
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| AssetsUSD | 148,862,000Source | 225,596,000Source | 368,633,000Source | 169,391,000Source | 75,912,000Source | 105,955,000Source | 191,263,000Source | — | 130,940,000Source | 209,581,000Source | 105,114,000Source |
| Property, Plant and Equipment, NetUSD | 6,981,000Source | 6,857,000Source | 5,671,000Source | 6,886,000Source | 7,315,000Source | 6,216,000Source | 7,057,000Source | — | 6,618,000Source | 6,370,000Source | 8,096,000Source |
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 25,508,000Source | 55,881,000Source | 301,454,000Source | 28,468,000Source | 34,248,000Source | 20,955,000Source | 30,401,000Source | 48,200,000Source | 26,701,000Source | 40,235,000Source | 53,504,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 569,000Source | — | — | 569,000Source | — | — | — | — | 0Source | 1,034,000Source |
| Assets, CurrentUSD | 129,524,000Source | 150,565,000Source | 352,276,000Source | 149,066,000Source | 49,749,000Source | 88,740,000Source | 170,004,000Source | — | 112,666,000Source | 188,631,000Source | 79,821,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,477,000Source | 3,233,000Source | 2,741,000Source | 6,671,000Source | 1,732,000Source | 1,958,000Source | 3,807,000Source | — | 4,591,000Source | 3,057,000Source | 1,092,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,262,000Source | 14,376,000Source | 9,236,000Source | 12,709,000Source | 15,129,000Source | 9,884,000Source | 13,482,000Source | — | 10,525,000Source | 13,794,000Source | 16,547,000Source |
| Other Assets, NoncurrentUSD | 418,000Source | 298,000Source | 809,000Source | 38,000Source | 330,000Source | 458,000Source | 13,000Source | — | 458,000Source | 267,000Source | 392,000Source |
| LIABILITIES AND EQUITY | |||||||||||
| LiabilitiesUSD | 19,638,000Source | 24,600,000Source | 21,131,000Source | 20,350,000Source | 50,596,000Source | 18,108,000Source | 22,480,000Source | — | 20,970,000Source | 22,940,000Source | 50,716,000Source |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 3,000Source | 5,000Source | 3,000Source | — | 3,000Source | 3,000Source | — | 3,000Source | 3,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -309,777,000Source | -230,589,000Source | -379,070,000Source | -288,249,000Source | -213,117,000Source | -354,065,000Source | -266,995,000Source | — | -330,549,000Source | -246,684,000Source | -181,311,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 87,000Source | 338,000Source | -21,000Source | 2,000Source | 121,000Source | -18,000Source | — | — | 103,000Source | -129,000Source | 308,000Source |
| Stockholders' Equity Attributable to ParentUSD | 129,224,000Source | 200,996,000Source | 347,502,000Source | 149,041,000Source | -191,097,000Source | 87,847,000Source | 168,783,000Source | -174,673,000Source | 109,970,000Source | 186,641,000Source | -162,015,000Source |
| Additional Paid in Capital, Common StockUSD | 438,911,000Source | 431,244,000Source | 726,588,000Source | 437,285,000Source | 21,899,000Source | 441,927,000Source | 435,775,000Source | — | 440,413,000Source | 433,451,000Source | 18,988,000Source |
| Liabilities and EquityUSD | 148,862,000Source | 225,596,000Source | 368,633,000Source | 169,391,000Source | 75,912,000Source | 105,955,000Source | 191,263,000Source | — | 130,940,000Source | 209,581,000Source | 105,114,000Source |
| Current liabilities: | |||||||||||
| Liabilities, CurrentUSD | 11,119,000Source | 13,292,000Source | 14,581,000Source | 10,768,000Source | 10,827,000Source | 10,880,000Source | 12,204,000Source | — | 13,087,000Source | 12,253,000Source | 12,227,000Source |
| Operating Lease, Liability, CurrentUSD | 3,097,000Source | 3,614,000Source | 3,299,000Source | 3,536,000Source | 3,674,000Source | 3,024,000Source | 3,594,000Source | — | 3,015,000Source | 3,618,000Source | 3,596,000Source |
| Accounts Payable, CurrentUSD | 848,000Source | 1,215,000Source | 1,386,000Source | 1,215,000Source | 823,000Source | 2,286,000Source | 2,036,000Source | — | 355,000Source | 1,121,000Source | 614,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,519,000Source | 11,160,000Source | 6,550,000Source | 9,582,000Source | 11,869,000Source | 7,228,000Source | 10,265,000Source | — | 7,883,000Source | 10,570,000Source | 13,316,000Source |
| Other Liabilities, NoncurrentUSD | — | 73,000Source | — | — | 74,000Source | — | — | — | — | 73,000Source | 73,000Source |
| Additional Financial Items | |||||||||||
| Accrued Liabilities, CurrentUSD | 7,026,000Source | 8,344,000Source | 9,896,000Source | 5,838,000Source | 6,214,000Source | 5,559,000Source | 6,375,000Source | — | 9,600,000Source | 7,392,000Source | 8,017,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 123,000,000Source | 199,600,000Source | 349,400,000Source | 142,400,000Source | — | 86,800,000Source | 166,000,000Source | — | 108,000,000Source | 185,400,000Source | — |
| Short-term InvestmentsUSD | 97,460,000Source | 90,750,000Source | 47,940,000Source | 113,897,000Source | 12,308,000Source | 65,827,000Source | 135,562,000Source | — | 81,307,000Source | 145,193,000Source | 23,467,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 666,000Source | 628,000Source | 2,597,000Source | 2,431,000Source | 2,266,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,593,000Source | 2,052,000Source | 6,821,000Source | 6,980,000Source | 7,053,000Source |
| Changes in operating assets and liabilities: | |||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | 0Source | -1,034,000Source | 510,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,812,000Source | 41,000Source | -760,000Source | 519,000Source | -408,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -20,950,000Source | -19,841,000Source | -76,751,000Source | -55,032,000Source | -47,430,000Source |
| Cash flows from investing activities: | |||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 15,316,000Source | 9,971,000Source | 63,411,000Source | -120,463,000Source | -25,975,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 242,000Source | 511,000Source | 2,587,000Source | 642,000Source | 3,258,000Source |
| Cash flows from financing activities: | |||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -112,000Source | 239,000Source | 9,000Source | 162,226,000Source | 24,391,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -5,746,000Source | -9,631,000Source | -13,331,000Source | -13,269,000Source | -49,014,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 25,969,000Source | 56,139,000Source | 301,915,000Source | 28,929,000Source | 21,416,000Source | 30,862,000Source | 27,162,000Source | 40,493,000Source | 53,762,000Source |
| Additional Financial Items | |||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,631,000Source | 1,907,000Source | 1,865,000Source | 1,549,000Source | 1,593,000Source | 2,052,000Source | 6,821,000Source | 6,980,000Source | 7,053,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 123,000,000Source | 199,600,000Source | 349,400,000Source | 142,400,000Source | 86,800,000Source | 166,000,000Source | 108,000,000Source | 185,400,000Source | — |
| DepreciationUSD | — | — | 600,000Source | 600,000Source | 700,000Source | 600,000Source | 600,000Source | 600,000Source | 2,500,000Source | 2,400,000Source | 2,300,000Source |
| General and Administrative ExpenseUSD | — | — | 5,264,000Source | 4,811,000Source | 4,965,000Source | 4,949,000Source | 5,118,000Source | 5,119,000Source | 20,270,000Source | 17,205,000Source | 13,912,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 72,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,528,000Source | -17,472,000Source | -25,005,000Source | -21,254,000Source | -23,516,000Source | -20,311,000Source | -83,865,000Source | -65,373,000Source | -28,720,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,369,000Source | 863,000Source | 1,885,000Source | 1,556,000Source | 914,000Source | 1,860,000Source | 5,945,000Source | 1,909,000Source | 2,023,000Source |
| Operating ExpensesUSD | — | — | 22,897,000Source | 18,335,000Source | 26,890,000Source | 22,810,000Source | 24,430,000Source | 22,171,000Source | 89,810,000Source | 67,533,000Source | 64,163,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | -6,000Source | -1,000Source | -5,000Source | 2,000Source | -4,000Source | -14,000Source | 157,000Source | 195,000Source |
| Payments to Acquire InvestmentsUSD | — | — | — | — | — | — | 6,442,000Source | 18,518,000Source | 44,875,000Source | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 166,507,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 138,000Source | 138,000Source | 51,000Source | 10,000Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | -977,000Source | — | — | — | — | 0Source | -3,597,000Source | -707,000Source |
| Operating Lease, Expense | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 0Source | 251,000Source | 32,923,000Source |
| Operating Income (Loss)USD | — | — | -22,897,000Source | -18,335,000Source | -26,890,000Source | -22,810,000Source | -24,430,000Source | -22,171,000Source | -89,810,000Source | -67,282,000Source | -30,671,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -3,000Source | -6,000Source | -1,000Source | -5,000Source | 2,000Source | -4,000Source | -14,000Source | 157,000Source | 195,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | -65,373,000Source | -28,648,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 72,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,528,000Source | -17,472,000Source | -25,005,000Source | -21,254,000Source | -23,516,000Source | -20,311,000Source | -83,865,000Source | -65,373,000Source | -28,720,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.88Source | -0.92Source | -0.63Source | -0.87Source | -0.95Source | -0.83Source | -3.43Source | -5.81Source | -35.78Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.88Source | -0.92Source | -0.63Source | -0.87Source | -0.95Source | -0.83Source | -3.43Source | -5.81Source | -35.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 24,481,722Source | 18,896,829Source | 39,413,236Source | 24,378,823Source | 24,678,420Source | 24,341,978Source | 24,444,057Source | 11,258,851Source | 802,747Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 24,481,722Source | 18,896,829Source | 39,413,236Source | 24,378,823Source | 24,678,420Source | 24,341,978Source | 24,444,057Source | 11,258,851Source | 802,747Source |
| Additional Financial Items | |||||||||||
| General and Administrative ExpenseUSD | — | — | 5,264,000Source | 4,811,000Source | 4,965,000Source | 4,949,000Source | 5,118,000Source | 5,119,000Source | 20,270,000Source | 17,205,000Source | 13,912,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 83,900,000Source | 65,400,000Source | 28,700,000Source |
| Investment Income, NetUSD | — | — | 1,372,000Source | 1,846,000Source | 1,886,000Source | 1,561,000Source | 912,000Source | 1,864,000Source | 5,959,000Source | 5,349,000Source | 2,535,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,369,000Source | 863,000Source | 1,885,000Source | 1,556,000Source | 914,000Source | 1,860,000Source | 5,945,000Source | 1,909,000Source | 2,023,000Source |
| Operating ExpensesUSD | — | — | 22,897,000Source | 18,335,000Source | 26,890,000Source | 22,810,000Source | 24,430,000Source | 22,171,000Source | 89,810,000Source | 67,533,000Source | 64,163,000Source |
| Research and Development ExpenseUSD | — | — | 17,633,000Source | 13,524,000Source | 21,925,000Source | 17,861,000Source | 19,312,000Source | 17,052,000Source | 69,540,000Source | 50,328,000Source | 50,251,000Source |
| Total Revenue | — | — | — | — | — | — | — | — | — | — | — |
| Operating Lease, Expense | — | — | — | —Source | — | — | — | — | — | — | — |
Offerings
Registration 333-298088
Filing attachments
d102135dex991.htm · 8-K · 2026-10-27
Exhibit 99.1 Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK ® Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, updated longer-term data showed that durability of clinical response did not meet the threshold the Company required to support continued development Company shares d…
Read attachment ↗d159579dex410.htm · S-3 · 2026-08-06
Exhibit 4.10 A RTIVA B IOTHERAPEUTICS, I NC. AND _____________, A S W ARRANT A GENT F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT D ATED A S O F __________ A RTIVA B IOTHERAPEUTICS, I NC. F ORM OF D EBT S ECURITIES W ARRANT A GREEMENT T HIS D EBT S ECURITIES W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between A RTIVA B IOTHERAPEUTICS, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws …
Read attachment ↗d159579dex46.htm · S-3 · 2026-08-06
Exhibit 4.6 ARTIVA BIOTHERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d159579dex48.htm · S-3 · 2026-08-06
Exhibit 4.8 ARTIVA BIOTHERAPEUTICS, INC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ A RTIVA B IOTHERAPEUTICS, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between A RTIVA B IOTHERAPEUTICS, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and ha…
Read attachment ↗d159579dex49.htm · S-3 · 2026-08-06
Exhibit 4.9 ARTIVA BIOTHERAPEUTICS, INC. and _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ A RTIVA B IOTHERAPEUTICS, I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between A RTIVA B IOTHERAPEUTICS, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of […
Read attachment ↗artv-ex4_3.htm · 10-Q · 2026-08-06
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ARTIVA BIOTHERAPEUTICS, INC. Warrant Shares: Date of Issuance:, 2026 (such date, the “Issue Date”) Warrant No.: PF-[ ] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date, to subsc…
Read attachment ↗